Mark Anthony McCamish Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Mark Anthony McCamish.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Mark Anthony McCamish. Mark Anthony McCamish is a SVP & CMO in PDL BIOPHARMA, INC. ($PDLI) and a Director in AVADEL PHARMACEUTICALS PLC ($AVDL) and a President and CEO in Forty Seven, Inc. ($FTSV) and a Director in Vincera Pharma, Inc. ($LSAC).
Address: C/O PDL BIOPHARMA, INC. 34801 CAMPUS DRIVE FREMONT 94555 CA
Companies in which Mark Anthony McCamish is an Insider
AVADEL PHARMACEUTICALS PLC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Mark Anthony McCamish: Director
Holdings: 118,602 shares
Latest Transaction: Sep 18 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Forty Seven, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Mark Anthony McCamish: President and CEO
Holdings: 0 shares
Latest Transaction: Apr 07 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
PDL BIOPHARMA, INC.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Mark Anthony McCamish: SVP & CMO
Holdings: 7,500 shares
Current Value: $16,575
Latest Transaction: Aug 17 2007
$PDLI Market Capitalization: $367.50M
$PDLI Previous Close: $2.21
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Vincerx Pharma, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Mark Anthony McCamish: Director
Holdings: 0 shares
Latest Transaction: Dec 28 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Mark Anthony McCamish
Sentiment: All, AVDL, FTSV, PDLI, VINCU
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 28 2020 | LSAC | Vincera Pharma, In ... | McCamish Mark Anthony | Director | Option Exercise | A | 19.00 | 6,667 | 126,673 | 6,667 | |
| Sep 18 2020 | AVDL | AVADEL PHARMACEUTI ... | McCamish Mark Anthony | Director | Buy | P | 5.83 | 52,398 | 305,250 | 171,000 | 118.6 K to 171 K (+44.18 %) |
| Sep 18 2020 | AVDL | AVADEL PHARMACEUTI ... | McCamish Mark Anthony | Director | Buy | P | 5.73 | 118,602 | 679,969 | 118,602 | 0 to 118.6 K |
| Sep 14 2020 | AVDL | AVADEL PHARMACEUTI ... | McCamish Mark Anthony | Director | Option Exercise | A | 5.30 | 50,000 | 265,000 | 50,000 | |
| Aug 11 2020 | AVDL | AVADEL PHARMACEUTI ... | McCamish Mark Anthony | Director | Option Exercise | A | 8.48 | 42,000 | 356,160 | 42,000 | |
| Apr 07 2020 | FTSV | Forty Seven, Inc. | McCamish Mark Anthony | President and CEO | Option Exercise | D | 35.75 | 327,375 | 11,703,656 | 0 | |
| Apr 07 2020 | FTSV | Forty Seven, Inc. | McCamish Mark Anthony | President and CEO | Option Exercise | D | 8.76 | 184,516 | 1,615,899 | 0 |